Pillar 1 · The flagship

Blueprint Care

Your decision report, executed by a dedicated clinical team. Not a variant list, but the decision, the reasoning, the access routes and the people to carry it out.

Book a free consultation See the Signature tests

Your decision report, executed by a clinical team

Blueprint Care takes the complete molecular picture of your cancer and turns it into a ranked, sign-out-ready treatment plan. Then it puts a named clinical team beside you to act on it, monitor it, and adjust as things change.

It is fed by a Signature molecular test, or by your existing data through Decipher.

11decisions marked down

6intelligence layers

1signed plan

Page one of a Blueprint Care report on a desk, showing an Actionability Index of 9.2 out of 10, a first-line recommendation, the reasoning behind it, and the key molecular findings. — Page one: the Chief Oncologist Summary, built to be read in under a minute.

The questions a raw report cannot answer

A sequencing report says what mutations are present. Blueprint Care says what to do about them.

Which treatment should come first, and how confident is that call?
Which drugs are ruled out by this tumour’s biology?
Which recruiting trials match this exact profile?
Are there biosimilars or assistance programmes that make it affordable?
If the first line fails, what is the fallback and how will we know early?
Is there a hereditary signal that means my family should be tested?

Eleven things every Blueprint marks down

The same eleven decisions, every time, so nothing important is left implicit.

#	What we mark down	Why it matters
01	First-line therapy	The best-supported treatment to start, with a confidence rationale.
02	What to avoid	Therapies this tumour will resist, so time and money are not wasted.
03	Matched trials	Recruiting studies that fit this exact molecular profile.
04	Biosimilar options	Clinically equivalent, lower-cost alternatives available in India.
05	On-label vs off-label	Where a therapy is approved, and where it would be off-label or via trial.
06	Resistance plan	How the tumour may escape, and the serial testing to catch it.
07	Access and cost	Assistance programmes, schemes and a realistic out-of-pocket picture.
08	Hereditary flags	Signals that inherited risk testing is warranted for you and relatives.
09	Drug safety (PGx)	How you may metabolise key drugs, to dose safely and avoid harm.
10	Prognostic context	What the biology suggests, stated honestly and without false certainty.
11	Actionability Index	A single readout of how targetable this tumour is.

Six section groups

Inside the report

The report moves from what to do in the next sixty seconds through to the deepest biology. It opens with a one-page Chief Oncologist Summary: the Actionability Index, what to start, what to avoid, and urgent flags.

Group	What it covers
Summary and actions	The clinical bottom line and a visual treatment roadmap.
Test provenance	What was sequenced, panel scope, limitations, pipeline traceability.
Genomic landscape	TMB, MSI, mutational signatures and the copy-number picture.
Clinical variants	Every driver alteration, its evidence tier and its consequence.
Intelligence layers	Subtype, clonal architecture, immune evasion, synergy, pathway biology.
Therapy and access	Therapy matrix, immunotherapy index, trials, resistance forecast, India access.

Chief Oncologist Summary

What should happen next?

Page one is built to be read in under a minute: the Actionability Index, the recommended first-line direction, explicit contraindications and any urgent flags. Everything beneath it is the evidence for that page.

Actionability Index: One number for how targetable this cancer is, 0 to 100
Recommended direction: Ranked, with the reasoning attached
Contraindications: What this tumour will resist, stated as plainly as what it may respond to
Urgent flags: Anything that should change today rather than at the next appointment

Layer 01 of 06

Test Provenance

Know what was tested.

A result without its quality record is not interpretable. This layer states the sample, the panel scope, the per-gene coverage, the tumour fraction and the limit of detection, so a negative finding can be read for what it is worth.

Specimen: Blood or tissue, when it was taken, and how much tumour was in it
Panel scope: Which genes were assessed, and for which classes of alteration
Coverage: Per gene, not averaged across the panel
What was not assessed: Stated explicitly, because the most dangerous line in a report is the missing one

Layer 02 of 06

Genomic Landscape

See the tumour as a system.

Single variants read in isolation miss the shape of the disease. This layer carries mutational burden, microsatellite status, copy number events and mutational signatures, so the individual findings are read in context.

Tumour mutational burden: With the panel size and method stated, since the number is not comparable across assays
Microsatellite status: Stable or unstable, and by which method
Copy number events: Amplifications and deletions across the panel
Mutational signatures: The patterns that suggest an underlying process

Layer 03 of 06

Clinical Variants

Which alterations matter?

Every alteration is graded against AMP/ASCO/CAP, ESCAT and OncoKB together. Where those frameworks disagree, the report shows the disagreement rather than quietly picking the most favourable one.

Driver alterations: With the specific variant named, not only the gene
Evidence tier: Graded against three international frameworks
Concordance view: Where the frameworks agree, and where they do not
Variants of uncertain significance: Reported as uncertain rather than quietly omitted

Layer 04 of 06

Intelligence Layers

Connect the biology.

Public databases say what a variant is. They cannot say how a tumour will evolve, whether the immune system can see it, or which combination is worth the toxicity. Six layers add that, each stating what it needs and what it cannot do.

CloneTrace: Which alterations are founder events and which are later branches
PhenoMap and ImmunoLens: Molecular subtype, and whether the immune system can see the tumour
SynerGx: Combination benefit weighed against overlapping toxicity
TrialGraph: Matched to recruiting studies, filtered by prior therapy

Layer 05 of 06

Therapy and Access

Turn the plan into action.

A recommendation nobody can reach is not a recommendation. This layer maps each option to clinically equivalent biosimilars, patient assistance programmes and government schemes available in India, and names who is chasing what.

Matched therapy: With the evidence tier that supports it
Recruiting trials: Filtered by molecular profile and by prior treatment
Access mapping: Biosimilars, assistance programmes and schemes, for the Indian context
Named ownership: Who is doing what next, and by when

Layer 06 of 06

Select a layer to open it. Arrow keys move between layers.

Beyond public databases

Six intelligence layers

Public annotation tells you what a variant is. These layers tell you what to do about it.

CloneTrace™clonal architecture

Which mutations are founder events present in every cancer cell, and which are later branches, so therapy targets the trunk rather than a twig.

SynerGx™combination synergy

Which drug combinations offer real added benefit versus overlapping toxicity, scored as a net-benefit index.

PhenoMap™molecular subtype

The tumour’s biological subtype, which sharpens both treatment choice and prognosis.

ImmunoLens™immune readiness

Whether the immune system can see the tumour, combining antigenicity with intact antigen presentation, to predict immunotherapy response.

TrialGraph™trials and cohorts

Recruiting trials that fit this profile, plus a real-world picture of similar patients.

AccessMatch™access and economics

Biosimilars, assistance programmes and the realistic cost pathway in India.

The eight-step journey

Step 1Free consultation
We choose the right starting test, or use your existing data.
Step 2Sample
A blood draw at home or in clinic, or your existing tissue block.
Step 3Sequencing
An accredited laboratory reads the DNA with transparent quality control.
Step 4Engine
Annotation, matching, and the six intelligence layers.
Step 5KPCIRC sign-out
A molecular tumour board authors and signs the plan.
Step 6Your report
The full document plus a plain-language version in your language.
Step 7Navigator sessions
Someone walks you and your family through results and access.
Step 8Continue
Sentinel, Clear and Heritage extend the same care.

Video to come

Meet your navigator

Ratio16/9Length2 minutes

Film briefLaunch blocker

Two-minute piece with a real OnKommon navigator, in the first person, on what they actually do in a week. The most reassuring asset on the site, so it should feel like meeting a person.

Handheld, on location. One camera, natural light, lapel mic.

Must be in frame

A named, real navigator speaking in the first person
Concrete detail from an actual week
Burnt-in captions plus subtitle tracks in four regional languages

Must not be

A studio set or a script that sounds written
Any outcome claim, or a patient identifiable without consent

Draft alt text: A patient navigator at her desk, and three moments from her week: calling a hospital pathology team about a tumour block, completing patient assistance paperwork, and sitting with a family after a result.
Consent and rights: Written release from every identifiable person, plus site permission from the facility. Nothing filmed in a clinical area while real patients are present.

Before launch: Save the supplied photograph as assets/img/navigator-priya.jpg and rebuild. The brief above is replaced automatically once the file is present.

Three ways in

Blood

A simple draw. No surgery, repeatable, ideal when tissue is hard to get. See the blood tiers.

Tissue

If you have a tumour block, Signature STt O profiles it comprehensively.

Existing data

Already tested elsewhere? Decipher builds the full report from your results, with no resequencing.

What the relationship includes

A dedicated navigator and in-person sessions.
Your report in your regional language, written for you and your family.
A clear management timeline so you know what happens next.
Genetic counselling through KPCIRC where hereditary risk is flagged.
Financial navigation: biosimilars, assistance programmes and schemes.
Second opinions on demand, provided by KPCIRC on a paid basis.

Standard report vs Blueprint Care

	Blueprint Care	A standard report
Output	Ranked, signed decision and plan	A variant list
Interpretation	Six proprietary intelligence layers	Left to the reader
Accountability	KPCIRC licensed sign-out	Often unclear
Trials and biosimilars	Matched and marked down	Rarely included
India cost pathway	Assistance programmes and schemes surfaced	Not addressed
Language	Plus a regional-language summary	Technical English
Afterwards	A navigator and continuous coordination	You are on your own

Built for India

Precision oncology is only real if you can reach it. We pair expensive targeted therapies with CDSCO-approved biosimilars where clinically equivalent, file the paperwork for assistance programmes, and map state and private schemes.

What is included, and who signs

Research and evidence

The science behind this

Comprehensive profiling reviewed by a molecular tumour board has been studied in thousands of patients.

Study 1

Tumour board review improved outcomes

In 715 patients with advanced cancer, closer matching between therapy and molecular profile on board advice gave better response and longer survival.

Kato S, et al. Nature Communications, 2020.

Study 2

Higher matching, better results

In treatment-refractory cancers, patients whose therapy targeted more of their specific alterations had significantly longer progression-free and overall survival.

Sicklick JK, et al. (I-PREDICT) Nature Medicine, 2019.

Study 3

What the overall evidence shows

A systematic review found board review appears to improve outcomes, while calling for more prospective randomized trials.

Systematic review, JCO Precision Oncology, 2021.

These independent, peer-reviewed studies describe the class of technology we use. They are shared for education. They are not results for any individual and not a promise of benefit.

Being clear about our limits

What we do and do not do

What we DO

Turn results into a ranked, signed treatment plan
Match your profile to therapies, trials and biosimilars in India
Give you a named navigator and a regional-language summary
Provide serial monitoring to follow the plan over time

What we DON’T do

Diagnose cancer or prescribe medicines
Guarantee a drug will be available, approved, covered or effective
Replace your oncologist or the tumour board sign-out
Act as an emergency service

Plain-language glossary (6 terms)

Term	What it means
MTB	Molecular tumour board, the specialist panel that signs your plan.
CGP	Comprehensive genomic profiling, reading many cancer genes in one test.
TMB	Tumour mutational burden, how many mutations a tumour carries.
MSI / MMR	Signals of faulty DNA repair that often predict immunotherapy response.
ctDNA	Circulating tumour DNA, tumour fragments a blood test can read.
Actionable	A finding with a matched drug, a trial, or a clear management step.

Important information and regulatory status

Blueprint Care and the Signature tests that feed it is a genomic (DNA-based) test for use by qualified healthcare professionals. It supports clinical judgement, it does not replace it, and it must be read alongside your full clinical history and applicable guidelines.

A result is not a diagnosis and does not by itself decide treatment.
A “not detected” result does not rule out cancer or a genetic change.
Not all cancers release enough DNA into blood to be detected.
We cannot guarantee that a medicine will be available, approved, covered or effective.
Collection kits are for qualified phlebotomists. They are not for self-testing.
Confirmatory testing may be required.

Regulatory status (India). Registration of our genomic tests as in-vitro diagnostic (IVD) medical devices with CDSCO is in progress, with the IVD class pending. Sequencing and variant calling are done by an accredited laboratory partner holding NABL (ISO 15189), CAP and CLIA accreditation, following ACMG/AMP/ASCO/CAP guidelines and a CE-IVD certified variant database. The OnKommon interpretation engine is provided for research and decision-support use. Marketing follows the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954.

Take the next step

Three ways forward. Pick the one that fits today.

Book a free consultation

A no-obligation conversation with our care team, arranged through KPCIRC.

Book a consultation

Begin Blueprint Care

Commission your decision report and a dedicated clinical team.

Explore Blueprint Care

Ask on WhatsApp, free

Signal replies to your first question within four hours, at no cost.

Start with Signal